all types of cancer treated with an oral anticancer agent
Conditions
Interventions
Group 1: Control group: standard therapy (patient care according to the standard of care
education and information about newly prescribed oral anticancer drug by prescribing physician, no additional advice from pharmacists / pharmacologists)
Group 2: Intervention group: intensive clinical
Sponsors
Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Initiation of therapy with an oral anticancer agent, cancer diagnosis, adult patient, planned duration of therapy / estimated lifespan of at least 4 months, ability to complete questionnaires
Exclusion criteria
Exclusion criteria: Prolonged inpatient stay and concomitant i.v. chemotherapy with classical cytostatic drugs, lack of german language skills, cognitive impairment, non-consenting patients, patients who are not able to take their medicine on their own, pregnant / lactating women, missing written consent
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| patient knowledge (SIMS-D questionnaire after 12 weeks), adherence (MARS-D questionnaire after 12 weeks), quality of life (QLQ-C30 questionnaire after 12 weeks) | — |
Primary
| Measure | Time frame |
|---|---|
| drug related problems (DRP) (number of DRP per patient after 12 weeks), satisfaction with anticancer therapy (TSQM VII questionnaire after 12 weeks) | — |
Countries
Germany
Contacts
Public ContactPauline Dürr
Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg
Outcome results
None listed